Skip to content
OpenCapital
Get started

GeneDx Holdings WGS Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

Illumina logo
IlluminaILMN
——
Guardant Health logo
Guardant HealthGH
——

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$1.89B-24.3%
Enterprise value$1.89B-22.8%
P/S4.3×-3.3×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%—
Net margin-17.6%—
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%—
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GeneDx Holdings's share-based payment - unrecognized cost of nonvested awards?
GeneDx Holdings (WGS) reported share-based payment - unrecognized cost of nonvested awards of $0 in Q1 2026.
How has GeneDx Holdings's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
GeneDx Holdings's share-based payment - unrecognized cost of nonvested awards decreased by 100.0% year-over-year, from $400K to $0.
What does share-based payment - unrecognized cost of nonvested awards mean?
This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.